Genmab A/S Approves 2024 Annual Report and Strategic Proposals at AGM

Genmab ( (GMAB) ) just unveiled an announcement.

On March 12, 2025, Genmab A/S held its Annual General Meeting in Copenhagen, where several key decisions were made. The 2024 Annual Report was approved, and the year’s profit of DKK 7,844 million was carried forward. The meeting saw the re-election of six board members and Deloitte as the company’s auditor. Additionally, proposals to amend the Remuneration Policy, reduce share capital, acquire treasury shares, and issue warrants were adopted. These decisions are expected to impact Genmab’s operational strategies and stakeholder interests positively.

More about Genmab

Genmab A/S is an international biotechnology company headquartered in Copenhagen, Denmark, with a focus on developing innovative and differentiated antibody therapeutics. Established in 1999, the company has a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators. Genmab aims to transform the lives of people with cancer and other serious diseases by 2030.

YTD Price Performance: -3.52%

Average Trading Volume: 1,469,787

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $12.84B

For detailed information about GMAB stock, go to TipRanks’ Stock Analysis page.